Abiomed signs $16m+ Japanese deal:
This article was originally published in Clinica
Abiomed, the Danvers, Massachusetts-based maker of temporary cardiac support systems, has signed a distribution deal for Japan that it said could be worth more than $16m. Local distribution company Medix Japan will carry out clinical trials and eventually distribute Abiomed's Impella and AB5000 circulatory support systems. It has agreed to purchase at least $11m-worth of Impella products in the first 18 months following their Japanese regulatory approvals, and has also committed to purchasing other products beginning in Abiomed's fiscal first quarter (ie, between April and June 2007).
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.